Product Details

Mvasi 400mg

Manufacturer: AMGEN

MFG#: 55513-0207-01

NDC: 55513-0207-01

PID: 639377

1/EA

$1,333.17

In Stock
$1,333.17

Additional Information

Product NameMvasi 400 mg
Active IngredientBevacizumab-awwb
Drug ClassAnti-VEGF Monoclonal Antibody
Mechanism of ActionBinds VEGF-A, inhibiting angiogenesis and tumor blood vessel formation
Strength400 mg per 16 mL
Volume16 mL
Route of AdministrationIntravenous infusion
Side EffectsHypertension, fatigue, diarrhea, proteinuria, bleeding, delayed wound healing
PrecautionsRisk of GI perforation, hemorrhage, thromboembolism, impaired wound healing
StorageRefrigerate at 2°C to 8°C; do not freeze; protect from light
PackagingSingle-use glass vial
UsesTreatment of colorectal cancer, NSCLC, glioblastoma, renal cell carcinoma, cervical cancer

Description

Mvasi 400 mg/16 mL vial is a biosimilar to bevacizumab, a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A). It is designed to inhibit angiogenesis, a process critical for tumor growth and metastasis. By binding to VEGF-A, Mvasi prevents interaction with its receptors on the surface of endothelial cells, thereby reducing the formation of new blood vessels.

This anti-angiogenic activity helps to starve tumors of the oxygen and nutrients required for their growth and proliferation. Mvasi is administered via intravenous infusion and is used in combination with chemotherapy for the treatment of various cancers, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, renal cell carcinoma, and cervical cancer.

Common side effects include hypertension, fatigue, diarrhea, and stomatitis. Serious adverse events may involve gastrointestinal perforations, hemorrhage, and thromboembolic events. The product must be stored refrigerated at 2°C to 8°C, protected from light, and should not be frozen.

Frequently Asked Questions (FAQs)

The cost of Mvasi 400mg is $$1,333.17

Mvasi 400mg is manufactured by AMGEN.